Antibody-drug conjugate trial starts

RecordSTO-GGHQZTVZBW-E74PT76P67-AJB5ED

176

Global · 2022

Antibody-drug conjugate trial starts worldwide were 176 in 2022 (ClinicalTrials.gov).

Original source

Publisher: ClinicalTrials.gov
Authority tier: T1 Official
Report: ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country
Locator: totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country.
Retrieved: 27 Sep 2026
Status: Verified

What the source says

{"totalCount":176,"studies":[
ClinicalTrials.gov (U.S. National Library of Medicine), ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country, totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country.

Checked: the figure 176 is stated in this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

APA

ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_GGHQZTVZBWE74PT76P67AJB5ED

Other formats: MLA, Chicago, BibTeX

MLA: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country." 2022, https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Accessed 27 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_GGHQZTVZBWE74PT76P67AJB5ED.
Chicago: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country." 2022. https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Accessed September 27, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_GGHQZTVZBWE74PT76P67AJB5ED.
BibTeX: @misc{clinicaltrialsgo2022ctgovajb5ed, author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}}, title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country}, year = {2022}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_GGHQZTVZBWE74PT76P67AJB5ED}, note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\%22antibody-drug\%20conjugate\%22\%20OR\%20\%22antibody\%20drug\%20conjugate\%22\%20OR\%20deruxtecan\%20OR\%20vedotin\%20OR\%20govitecan\%20OR\%20emtansine\%20OR\%20ozogamicin\%20OR\%20tesirine\%20OR\%20mafodotin\%20OR\%20soravtansine\%20OR\%20tirumotecan\%20OR\%20rezetecan\%20OR\%20\%22SKB264\%22\%20OR\%20\%22SHR-A1811\%22\%20OR\%20\%22BL-B01D1\%22\%20OR\%20izalontamab\%20OR\%20disitamab\%20OR\%20\%22trastuzumab\%20deruxtecan\%22\%20OR\%20DS-8201\%20OR\%20T-DXd\%20OR\%20SHR-A1811\%20OR\%20\%22trastuzumab\%20rezetecan\%22\%20OR\%20\%22sacituzumab\%20tirumotecan\%22\%20OR\%20SKB264\%20OR\%20sac-TMT\%20OR\%20MK-2870\%20OR\%20\%22disitamab\%20vedotin\%22\%20OR\%20RC48\%20OR\%20\%22sacituzumab\%20govitecan\%22\%20OR\%20IMMU-132\%20OR\%20\%22enfortumab\%20vedotin\%22\%20OR\%20BL-B01D1\%20OR\%20\%22datopotamab\%20deruxtecan\%22\%20OR\%20Dato-DXd\%20OR\%20DS-1062\&filter.advanced=AREA\%5BStudyType\%5DINTERVENTIONAL\%20AND\%20AREA\%5BStartDate\%5DRANGE\%5B2022-01-01\%2C2022-12-31\%5D\&countTotal=true\&pageSize=1\&fields=NCTId. Accessed September 27, 2026.} }

Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Primary source

Publisher: ClinicalTrials.gov (U.S. National Library of Medicine) · homepage ↗
Authority tier: Tier 1 · Multilateral Official
Report: ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country
Type: Dataset
Published: —
Locator: totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country.
Retrieved: 27 September 2026
Link status: Reachable (HTTP 200)
Report licence: Public domain

Verification

Status: Verified
Review protocol: pipeline:ctgov-api-totalcount-verified
Checked on: 27 September 2026
Last revision: 27 September 2026
Permanent URL: /stat/stat_GGHQZTVZBWE74PT76P67AJB5ED

Same indicator, other countries

2022 figures for the same indicator, ranked highest first.

Country or region	Value	Source	Details
United States	96	ClinicalTrials.gov	Open record
China	69	ClinicalTrials.gov	Open record

This figure in context

Cited in

Antibody-drug conjugates: China now hosts more new ADC trials than the United States

Go further

Record last modified 27 September 2026. Value type: actual. Update cadence: irregular. This page is permanently addressable at statorigin.org/stat/stat_GGHQZTVZBWE74PT76P67AJB5ED.